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Novel coumarin–benzimidazole derivatives as antioxidants and safer anti-inﬂammatory agents 3691. Introduction
Inﬂammation is an important indication in many pathological
conditions such as rheumatoid arthritis, osteoarthritis, gout, Alzhei-
mer's disease and obesity related diseases1. Chronic inﬂammatory
states lead to a vicious cycle of inﬂammation and the accompanying
pathological states, like obesity can lead to inﬂammation and the
chronic inﬂammation can promote obesity associated diabetes by
inducing insulin resistance2. Therefore, control of inﬂammation
becomes more important in all pathological conditions. The well-
known non-steroidal anti-inﬂammatory drugs (NSAIDs) viz. indo-
methacin, ibuprofen and naproxen are commonly employed drugs in
ﬁrst line treatment of various chronic inﬂammatory disease states3.
The major limitation of use of NSAIDs is gastric intolerance, which
is manifested by dyspepsia, bleeding and ulcers. It occurs due to
prostaglandin synthesis blockade as a result of cyclooxygenase (COX)
inhibition by NSAIDs as well as due to acidic character of the NSAIDs
themselves4. Users of NSAIDs are found to be at 3 times greater risk of
developing serious gastro-intestinal (GIT) adverse effects than the non-
users5. Another statistical analysis displays that 23%–31% of patients
develop gastric lesions when prescribed NSAIDs for arthritis6. All
these facts have arose the need to improve the safety proﬁle of existing
NSAIDs or to discover better alternatives. Various COX-2 selective
inhibitors have exhibited marked anti-inﬂammatory effect with reduced
GIT toxicity. MK-0966, rofecoxib and celecoxib are selective COX-2
inhibitors with signiﬁcant anti-inﬂammatory activity but induce less
GIT side-effects in comparison to those of aspirin and ibuprofen7,8.
Coupling of NSAIDs with an antioxidant cysteamine has produced
compounds having good activity with less GIT intolerance. Coupling
of nitric oxide, a cellular antioxidant with NSAIDs has also been
explored successfully to design anti-inﬂammatory agents with mark-
edly reduced ulcerogenic potential4,9.
Coumarins form an elite class of compounds, which exhibit a
variety of therapeutic activities including antioxidant, anti-inﬂam-
matory, antitumor, antiviral, antituberculosis and antimicrobial10–13.
Anti-inﬂammatory activity of coumarin derived compounds has
been reviewed extensively and a structure activity relationship
(SAR) has been established wherein it is found that an aromatic
group when directly fused or linked through amide linkage at
3-position of coumarin nucleus incurs anti-inﬂammatory activity
(Fig. 1)14–16. Many such derivatives also possess antioxidant
activity through scavenging mechanisms17,18.
Benzimidazole is another multifacet nucleus possessing a wide
range of biological activities19. This nucleus bearing at its 2-
position a heterocycle through linker has been found in many
clinically available antiulcer drugs. It reveals that benzimidazole
substituted with an appropriate group at 2-position is an important
structural feature for gastric safety of the molecule20. Therefore,
the present study is undertaken to design novel molecules through
coupling of 2-position of benzimidazole nucleus with 3-position of
6-substituted coumarin nucleus (Fig. 1), which can be exploited as
viable alternatives to the existing NSAIDs. The resultant mole-
cules are expected to exhibit both anti-inﬂammatory and antiox-
idant activities but still being less gastro-toxic.2. Results and discussion
2.1. Chemistry
The target compounds were synthesized as shown in Scheme 1.
Initially, Meldrum's acid (1) was prepared by treating malonic acidwith acetone in the presence of catalytic amounts of sulphuric acid and
acetic anhydride. Different salicylaldehydes (2a–e) were reacted with 1
in the presence of piperidinium acetate to obtain 6-substituted
coumarin-3-carboxylic acids (3a–e). These intermediates were then
used to synthesize target compounds 4a–e by reﬂuxing them with o-
phenylenediamine under inert environment (nitrogen) in the presence
of catalytic amounts of polyphosphoric acid (PPA). The target
compounds 5a–e were synthesized by coupling these intermediates
with 2-aminobenzimidazole in the presence of dicyclohexylcarbodii-
mide (DCC) and 4-dimethylaminopyridine (DMAP). Many literature
reports reveal the use of both orthophosphoric acid (OPA) and PPA for
the formation of benzimidazole nucleus21,22. In the present study, PPA
was used as catalyst as OPA produced more by products and took
longer reaction times. All target compounds were obtained in good
yields and were found to be pure as assured by single spots in thin
layer chromatographic plates (TLC). Structures of the synthesized
compounds were conﬁrmed by IR, NMR and high resolution mass
(HRMS) spectral techniques. Formation of benzimidazole nucleus in
compounds 4 and 5 was ascertained by the disappearance of –COOH
band, due to –COOH group of compounds 2, in their IR spectra. In
addition, IR spectra of 5 showed an amide band in the range of 1640–
1690 cm1. Presence of benzimidazole nucleus was conﬁrmed by
appearance of signals due to –NH and four aromatic protons of the
nucleus in their 1H NMR spectra. The labile –NH protons were
detected in the range of δ 8.9–9.2, which was conﬁrmed by deuterium
exchange experiments. The 13C NMR spectra showed distinct
resonances in agreement with the proposed structure. The methoxy
derivatives 4b and 5b showed distinct peaks due to methoxyl carbon at
around δ 55. The benzimidazole carbons were detected at δ 116.21–
125.51, and the coumarinyl carbonyl carbon was found at δ 155.62–
164.05. Carbon atoms of the benzene ring of coumarin nucleus showed
downﬁeld or upﬁeld shifts in consonant with the type of substituent
present on the ring. Finally, the HRMS data, recorded with electrospray
ionization in positive polarity (þESI), of each compound showed that
the mass of [MHþ] ion was in close agreement with its accurate
theoretical mass.
2.2. Anti-inﬂammatory activity
It was evaluated in terms of percent (%) inhibition of formalin induced
oedema in rat paw. The activity was monitored at 0.5, 1, 2, 4 and 6 h
after administration. It was found that the activity continuously
increased with time. All test compounds exhibited good to moderate
anti-inﬂammatory activity, which was comparable to indomethacin at
each time period (Fig. 2). Further, the inhibition proﬁle of each
compound was similar to that of indomethacin at each time slab,
which suggested that the mechanism of action of the compounds
might be similar to that of indomethacin. Compounds 4a–e showed
anti-inﬂammatory effects better than those of compounds 5a–e.
Compounds 4d and 4c were maximally potent with 46.75% and
45.45% inhibition of paw oedema, respectively. From the other series,
compound 5a was the most potent with 42.85% inhibition. These
results suggest that an electron withdrawing group (–Cl or –Br)
increases the anti-inﬂammatory potency whereas electron releasing
group (–OCH3) decreases the potency. Further, it was found that an
amide linkage in the molecule decreased the activity.
2.3. In vitro antioxidant activity
The antioxidant potential was evaluated as radical scavenging capacity
using 2,2-diphenyl-1-picrylhydrazyl (DPPH) method. DPPH being
Figure 1 Design strategy for the target compounds.
Scheme 1 Synthesis of test compounds 4 and 5.
Radha Krishan Arora et al.370composed of unstable free radical traps any radicals produced by the
test compound and bring about a visible colour change ranging from
violet to pale yellow to colourless. The degree of change in absorbance
with respect to control is calculated as antioxidant potential. Due to the
non-linear relationship in the DPPH method, probit regression was
applied and EC50 values were calculated using BLeSq software
23.
Series 5a–e is found to be more potent than series 4a–e as depicted in
Table 1. Compounds 4d and 5a were found to be most potent with
EC50 value 13.9271.4 μmol/L and 1.270.1 μmol/L, respectively. The
study reveals that electron withdrawing groups increase the antioxidant
potential which may be due to the intensiﬁcation of positive charge on
–NH of amide associated with negative inductive effect of thesegroups. The positive charge intensiﬁcation may lead to free radical
quenching. Moreover, electron withdrawing groups are themselves
good free radical quenchers. On the contrary, substitution with electron
releasing groups was found to decrease the radical scavenging potential
possibly due to their positive inductive effect.2.4. Gastric safety and in vivo oxidative stress
Based on anti-inﬂammatory and in vitro antioxidant activities, the
compounds 4c, 4d and 5a were selected for evaluation of gastric
safety as well as in vivo oxidative stress. The compounds 4d and
Figure 2 Anti-inﬂammatory effect of compounds of series 4 and 5. Values are represented as mean7SD (n¼6). aValues are statistically
different from standard at each time interval, Po0.05.
Table 1 In vitro antioxidant activity by DPPH method.
Compound Inhibition (%) EC50
a (mmol/L)
1 mmol/L 2 mmol/L 5 mmol/L 10 mmol/L 20 mmol/L 50 mmol/L
4a 2.270.1 7.570.4 25.271.6 47.173.3 62.876.4 69.574.4 15.571.5
4b 15.170.5 17.270.6 22.971.2 25.571.8 28.771.3 35.371.5 450.0
4c 1.670.1 6.170.2 19.871.8 37.873.1 56.273.0 65.474.3 19.771.7
4d 0.770.1 4.170.3 22.070.8 32.672.7 63.873.6 70.174.3 13.9271.4
4e 0.470.01 3.870.2 18.871.8 37.272.5 50.974.7 59.573.0 22.571.7
5a 45.373.8 55.872.2 64.174.0 69.074.8 71.672.8 75.873.7 1.270.1
5b 0.770.04 2.770.1 22.1970.4 30.074.0 39.071.9 56.373.9 28.571.8
5c 36.070.9 55.873.0 64.572.4 68.072.5 71.174.9 75.974.4 1.970.1
5d 17.270.6 41.373.0 60.173.6 71.873.4 76.375.4 90.574.9 4.070.4
5e 25.470.6 42.771.5 55.072.3 59.773.8 64.173.4 75.974.9 5.070.5
BHTb 5.670.7 19.271.8 28.071.7 37.572.8 48.973.7 60.472.9 23.473.1
aEC50, concentration which possesses 50% radicle scavenging ability.
bButylatedhydroxytoluene.
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low ulcer index (0.67 and 0.75, respectively) in comparison to
indomethacin which has scored an ulcer index of 3.17 (Table 2).
The increased catalase and glutathione levels and decreased
thiobarbituric acid reactive substances (TBARS) levels in animals
treated with standard drug with respect to the control group
indicated that indomethacin had induced oxidative stress in the
tissues. In consonant with the gastric safety proﬁle, the compounds
4d and 5a have been found to exert no oxidative stress on the
tissue as indicated by the catalase, glutathione and TBARS levels
being almost equal to those of control group.
These results indicated the compounds 4d and 5a to be
maximally safe on gastric mucosa as well as inducing negligible
oxidative stress. The lower gastric safety and relatively poor
oxidative stress parameters of compound 4c may be attributed to
the presence of bromo group in the molecule.2.5. Molecular properties calculation
“Lipinski's rule of 5” predicts oral bioavailability, intestinal
absorption and blood brain barrier permeability of a new molecule
through its molecular properties that include lipophilicity (log P),
total polar surface area (TPSA), nON (number of H-bondacceptors), nOHNH (number of H-bond donors) and molecular
weight. These properties are calculated using molinspiration
calculations software24,25. Log P and TPSA are the two most
important properties for this prediction. TPSA is closely related to
hydrogen bonding potential of a compound. Molecules with TPSA
of about 160 Å or more are expected to have poor intestinal
absorption26.
All compounds have been found to have nON and nOHNH in
the ranges of 4–9 and 1–2, respectively, molecular weights less
than 400, Log P in the range of 2.5–4.3, and TPSA in the range of
58–133 (Table 3). Moreover, all the compounds have zero
violation of this rule. Hence, these parameters suggest that the
compounds are expected to exhibit good oral bioavailability and
intestinal absorption.3. Conclusions
Two series of compounds were designed and synthesized by
conjugating coumarin at 3-position with benzimidazole at 2-position
through a single bond (series 4) as well as an amide linkage (series 5).
The series 4 was found to possess anti-inﬂammatory activity better than
the series 5. Compounds 4c, 4d and 5a exhibited maximum inhibition
of inﬂammation. On the contrary, series 5 exhibited very potent
Table 2 Biochemical estimations and ulcer index of 4c, 4d and 5a.
Compound Catalase (mmol/L/mg) TBARS (nmol/L/mg) Glutathione (mmol/L/100 mg) Ulcer index
Control 22.1470.98 0.6370.09 184.1075.03 0.1770.25
Standard (ID) 7.7970.19 5.3270.11 85.2073.10 3.1771.03
4c 15.8373.21a,b 1.6770.15a,b 87.0974.04a 2.2570.31a,b
4d 20.4672.02b 0.9870.02a,b 169.8475.09a,b 0.6770.25a,b
5a 21.9671.70b 0.8970.07a,b 176.4173.19a,b 0.7570.25a,b
aValues are statistically different from control, Po0.05.
bValues are statistically different from standard drug, Po0.05.
Table 3 TPSA and molecular properties of test compounds.
Compound TPSAa Log Pb MWc nONd nOHNHe n violf n rotbg
4a 58.894 3.549 262.268 4 1 0 1
4b 68.128 3.582 292.294 5 1 0 2
4c 58.894 4.334 341.164 4 1 0 1
4d 58.894 4.203 296.713 4 1 0 1
4e 104.718 3.484 307.265 7 1 0 2
5a 87.992 2.645 305.293 6 2 0 2
5b 97.226 2.677 335.319 7 2 0 3
5c 87.992 3.43 384.189 6 2 0 2
5d 87.992 3.299 339.738 6 2 0 2
5e 133.816 2.58 350.29 9 2 0 3
aTotal polar surface area.
bLipophilicity.
cMolecular weight.
dHydrogen bond aceeptors.
eHydrogen bond donors.
fNumber of violations.
gNumber of rotatable bonds.
Radha Krishan Arora et al.372antioxidant activities with 5a being the most potent and even more
active than the standard compound BHT. SAR was established on the
basis of the results obtained. Maximally potent compounds were found
to be safe on gastric mucosa with least ability to induce oxidative stress
in tissues except compound 4c. All compounds possessed sufﬁciently
good oral bioavailability and hence, compounds 4d and 5a could be
taken as lead for development of potent anti-inﬂammatory and
antioxidant activities yet being safe to gastric mucosa.4. Experimental
The reagents and solvents were of laboratory grade and were procured
from different suppliers (LobaChemie, Mumbai; SD Fine, Mumbai;
Merck, Mumbai). Melting points were determined in open capillaries
using Digital Auto Melting Point Apparatus (Labtronics) and are
uncorrected. Purity of the compounds was ascertained by TLC using
precoated aluminium TLC plates visualized in a UV/Iodine chamber.
Infrared spectra were recorded on an Alpha-E FTIR spectrophotometer
(BrukerOptik, Germany) using potassium bromide optics. 1H and 13C
NMR spectra were recorded on a BrukerAvance II spectrometer
(400 MHz) using tetramethylsilane (TMS) as internal standard and
chemical shifts are given in ppm. Mass spectra were recorded using a
Q-TOF micromass spectrometer (Waters, MA, USA).Wistar rats (150–250 g) of either sex were employed for the
study. They were exposed to 12 h light/dark cycle and the animals
had free access to food and water. The animals were given
standard laboratory pellet chow diet and water ad libitum, both
being withdrawn 12 h prior to experiment. The experimental
protocol was duly approved by Institutional Animal Ethical
Committee and the care of animals was done as per guidelines
of Committee for the Purpose of Control and Supervision of
Experiments on Animals, Government of India. The animals were
administered orally with 20 mg/kg of indomethacin and the test
compounds at equimolar doses to standard drug.4.1. Chemistry
Synthesis of Meldrum's acid (1) and intermediate compound 3a
(2-oxo-2H-chromen-3-carboxylic acid) has been reported in litera-
ture27,28. Other derivatives of series 3 are novel compounds whose
spectral data are as follows:
6-Methoxy-2-oxo-2H-chromen-3-carboxylic acid (3b): Yield:
88%; pale yellow crystals; mp: 210–212 1C; 1H NMR: δ 11.32
(s, 1H), 8.69 (s, 1H), 7.39 (d, 1H, J¼2.88 Hz), 7.32–7.34 (m, 1H),
7.28 (dd, 1H, JA¼2.88 Hz, JB¼6.2 Hz), 3.83 (s, 3H); 13C NMR:
δ 162.78, 158.53, 155.62, 148.09, 124.26, 122.35, 119.02, 118.81,
118.06, 111.67, 55.83; IR (KBr): 3048, 2990, 2763–3048, 1758,
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C11H9Oþ5 : 221.0444, found 221.0378.
6-Bromo-2-oxo-2H-chromen-3-carboxylic acid (3c): Yield:
70%; mp: 194–196 1C; white crystals; 1H NMR: δ 9.59 (s, 1H),
8.57 (s, 1H), 7.94 (d, 1H, J¼2.32 Hz), 7.74 (dd, 1H, JA¼2.36 Hz,
JB¼6.48 Hz), 7.28 (d, 1H, J¼8.84 Hz); 13C NMR: δ 165.57,
157.23, 154.78, 136.72, 129.66, 127.87, 122.35, 120.59, 119.61,
119.29; IR (KBr): 3099, 2740–3099, 1759, 1678, 1556, 1204,
1029 cm1; HRMS (ESIþ) m/z: calcd. for C10H6BrOþ4 : 268.9444,
found 268.9377.
6-Chloro-2-oxo-2H-chromen-3-carboxylic acid (3d): Yield:
69%; white crystals; mp: 120–122 1C; 1H NMR: δ 9.29 (s, 1H),
8.51 (s, 1H), 7.87 (d, 1H, J¼2.52 Hz), 7.61 (dd, 1H, JA¼2.92 Hz,
JB¼6.32 Hz), 7.37 (d, 1H, J¼8.88 Hz); 13C NMR: δ 160.73,
159.89, 150.81, 134.99, 130.48, 127.62, 125.76, 121.83, 120.52,
120.08; IR (KBr): 3047, 2625–3047, 1755, 1682, 1562, 1237,
1079 cm1; HRMS (ESIþ) m/z: calcd. for C10H6ClOþ4 : 224.9949,
found 224.9880.
6-Nitro-2-oxo-2H-chromen-3-carboxylic acid (3e): Yield: 80%;
yellow crystals, mp 234–236 1C; 1H NMR: δ 10.69 (s, 1H), 8.83–
8.87 (m, 2H), 8.47 (dd, 1H, JA¼2.68 Hz, JB¼7.88 Hz), 7.58 (d,
1H, J¼9.12 Hz); 13C NMR: δ 160.96, 160.73, 157.89, 149.33,
128.34, 127.41, 122.54, 121.96, 121.62, 118.48; IR (KBr): 3115,
2865–3240, 1738, 1723, 1570, 1535, 1207 cm1; HRMS (þESI)
m/z: calcd. for C10H6NOþ6 : 236.0190, found 236.0123.4.1.1. Synthesis of test compounds 4a–e
Coumarin carboxylic acid, 3a–e (0.001 mol) was fused with o-
phenylenediamine (0.001 mol) in the presence of polypho-
sphoric acid (PPA) (1 g/mmol) under nitrogen. The reaction
mixture was reﬂuxed in an oil bath at 170–180 1C for 0.5–1 h,
cooled and poured into ice water. The resulting mixture was
basiﬁed to pH 8 with 25% ammonium hydroxide solution. The
precipitates were ﬁltered, washed with water and dried to get
crude product which was recrystallized from aqueous ethanol21.
The compounds were found to be pure conﬁrmed by spectral
data given below:
3-(1H-Benzo[d]imidazol-2-yl)-2H-chromen-2-one (4a): Yield:
75%; green amorphous solid; mp: 290–292 1C; 1H NMR: δ 9.20
(s, 1H, NH), 8.17 (s, 1H), 7.64–7.76 (m, 4H), 7.40–7.47 (m, 2H),
7.33–7.37 (m, 2H); 13C NMR: δ 162.26, 152.76, 146.12, 140.35,
139.93, 138.11, 130.56, 129.87, 128.61, 125.11, 123.81, 122.99,
119.26, 118.69, 117.68, 117.23; IR (KBr): 3120, 1740, 1600,
1568, 1261, 1226 cm1; HR-MS (þESI) m/z: calcd. for
C16H11N2Oþ2 : 263.0815, found 263.0824.
3-(1H-Benzo[d]imidazol-2-yl)-6-methoxy-2H-chromen-2-one
(4b): Yield: 65%; orange amorphous solid; mp: 192–194 1C; 1H
NMR: δ 9.16 (s, 1H, NH), 8.7 (s, 1H), 7.73–7.75 (m, 1H), 7.61–
7.62 (m, 1H), 7.50–7.53 (m, 1H), 7.42–7.44 (m, 1H), 7.35–7.38
(m, 1H), 7.28–7.30 (m, 1H), 6.78–6.95 (m, 1H), 3.88 (s, 3H); 13C
NMR: δ 164.05, 156.98, 155.72, 148.94, 148.17, 141.00, 141.00,
129.25, 123.10, 122.06, 122.06, 118.53, 118.53, 118.39, 117.27,
111.83, 55.8; IR (KBr): 3048, 2907, 1748, 1492, 1449, 1269,
1232 cm1; HR-MS (ESIþ) m/z: calcd. for C17H13N2Oþ3 :
293.0921, found 293.0925.
3-(1H-Benzo[d]imidazol-2-yl)-6-bromo-2H-chromen-2-one
(4c): Yield: 80%; yellow amorphous solid; mp: 240–242 1C; 1H
NMR: δ 9.15 (s, 1H), 8.29–8.34 (m, 2H), 7.88–7.91 (m, 1H),
7.71–7.76 (m, 1H), 7.55 (d, 2H, J¼8.84 Hz), 7.27–7.32 (m, 2H);
13C NMR: δ 163.87, 153.60, 152.37, 145.45, 141.00, 135.25,
135.25, 132.07, 131.49, 122.83, 122.83, 121.03, 119.95, 118.52,116.33, 116.33; IR (KBr): 3045, 1741, 1625, 1516, 1242, 1204,
1055 cm1; HR-MS (ESIþ) m/z: calcd. for C16H10BrN2Oþ2 :
340.9920, found 340.9929.
3-(1H-Benzo[d]imidazol-2-yl)-6-chloro-2H-chromen-2-one
(4d): Yield: 63%; green amorphous solid; mp: 258–260 1C; 1H
NMR: δ 9.39 (br s, 1H, NH), 7.75–7.78 (m, 2H), 7.62 (dd, each
2H, JA¼2.44 Hz, JB¼6.44 Hz), 7.40–7.42 (m, 2H), 7.25–7.27
(m, 2H); 13C NMR: δ 158.83, 151.83, 145.34, 140.87, 140.87,
138.39, 132.30, 128.75, 128.75, 128.37, 122.63, 122.63, 120.43,
118.12, 117.72, 117.72; IR (KBr): 3055, 1717, 1655, 1529, 1315,
1224, 1066 cm1; HR-MS (ESIþ) m/z: calcd. for C16H10ClN2Oþ2 :
297.0425, found 297.1436.
3-(1H-Benzo[d]imidazol-2-yl)-6-nitro-2H-chromen-2-one (4e):
Yield: 60%; brown amorphous solid; mp4290 1C; 1H NMR: δ
9.29 (s, 1H), 8.50 (d, 2H, J¼9.76 Hz), 7.75–7.85 (m, 2H), 7.54–
7.66 (m, 2H), 7.31–7.32 (m, 2H); 13C NMR: δ 162.92, 155.36,
146.68, 144.61, 143.77, 141.12, 140.36, 128.98, 14.58, 123.24,
122.82, 122.55, 122.55, 118.22, 118.22, 116.32; IR (KBr): 3119,
1750, 1646, 1546, 1497, 1330, 1220 cm1; HR-MS (ESIþ) m/z:
calcd. for C16H10N3Oþ4 : 308.0666, found 308.0615.4.1.2. Synthesis of test compounds 5a–e
A suspension of 3a–e (0.01 mol) and DCC (2.3 g, 0.011 mol) in
dried dichloromethane (DCM) (100 mL) was vigorously stirred for
30 min under nitrogen. A solution of 2-aminobenzimidazole
(0.01 mol) dissolved in dried DCM (30 mL) and freshly distilled
pyridine (50 mL) along with DMAP (0.050 g) was added to the
reaction mixture at 0 1C in 15 min. The solution was stirred at 0 1C
for 2 h followed by overnight stirring at room temperature. The
solution was ﬁltered to remove dicyclohexylurea and the ﬁltrate
was evaporated in vacuum to yield dry solid which was dissolved
in dried ethyl acetate with heating in a water bath. The residue was
ﬁltered and the ﬁltrate was washed with distilled water. The ethyl
acetate layer was dried with magnesium sulphate and evaporated
in vacuum. The resulting crude solid was recrystallized with
methanol to yield corresponding amide22. The spectral data of the
compounds of series 5a–e are as follows:
N-(1H-Benzo[d]imidazol-2-yl)-2-oxo-2H-chromen-3-carboxa-
mide (5a): Yield: 54%; yellow amorphous solid; mp: 198–200 1C;
1H NMR: δ 9.04 (s, 1H), 8.30 (s, 1H), 7.74–7.80 (m, 2H), 7.59–
7.62 (m, 1H), 7.54 (dd, 1H, JA¼1.44 Hz, JB¼6.32 Hz), 7.31–
7.38 (m, 2H), 7.24–7.26 (m, 2H), 6.45 (br s, 1H); 13C NMR: δ
163.21, 156.58, 153.25, 152.81, 143.57, 142.16, 132.97, 130.59,
125.87, 124.57, 124.57, 122.93, 118.39, 117.29, 116.21, 116.21,
114.81; IR (KBr): 3054, 1707, 1664, 1644, 1531, 1315,
1225 cm1; HR-MS (ESIþ) m/z: calcd. for C17H12N3Oþ3 :
306.2949, found 306.2889.
N-(1H-Benzo[d]imidazol-2-yl)-6-methoxy-2-oxo-2H-chromen-
3-carboxamide (5b): Yield: 51%; white amorphous solid; mp:
186–188 1C; 1H NMR: δ 8.96 (s, 1H), 8.17 (s, 1H), 8.0 (s, 1H),
7.84 (d, 1H, J¼7.96 Hz), 7.29–7.31 (m, 2H), 7.22–7.23 (m, 2H),
7.18–7.20 (m, 1H), 5.50 (br s, 1H), 3.81 (s, 3H); 13C NMR: δ
162.17, 159.43, 155.16, 152.83, 147.61, 138.26, 135.36, 124.93,
122.41, 122.41, 120.43,118.30, 117.24, 116.89, 116.53, 114.56,
111.20, 55.75; IR (KBr): 3055, 2889, 1707, 1643, 1640, 1531,
1372, 1339, 1227 cm1; HR-MS (ESIþ) m/z: calcd. for
C18H14N3Oþ4 : 336.3209, found 336.2987.
N-(1H-Benzo[d]imidazol-2-yl)-6-bromo-2-oxo-2H-chromen-3-
carboxamide (5c): Yield: 50%; pale white amorphous solid; mp:
202–204 1C; 1H NMR: δ 9.09 (s, 1H), 8.3 (s, 1H), 8.22 (s, 1H),
7.91–7.97 (m, 1H), 7.77–7.79 (m, 1H), 7.54–7.59 (m, 2H), 7.37–
Radha Krishan Arora et al.3747.40 (m, 2H), 5.57 (br s, 1H); 13C NMR δ: 162.96, 159.86,
152.78, 151.75, 137.24, 135.81, 134.61, 132.76, 125.51, 124.68,
123.87, 120.36, 119.36, 118.99, 116.37, 115.98, 115.62; IR (KBr):
3054, 1723, 1646, 1641, 1535, 1341, 1256, 1083 cm1; HR-MS
(ESI) m/z: calcd. for C17H11BrN3Oþ3 : 383.9978, found 383.9989.
N-(1H-Benzo[d]imidazol-2-yl)-6-chloro-2-oxo-2H-chromen-3-
carboxamide (5d): Yield: 61%; white amorphous solid; mp: 212–
214 1C; 1H NMR: δ 9.12 (s, 1H), 8.36 (s, 1H), 8.10 (s, 1H), 7.50–
7.52 (m, 1H), 7.38–7.40 (m, 1H), 7.33–7.36 (m, 2H), 7.21–7.25
(m, 2H), 5.42 (br s, 1H); 13C NMR: δ 163.60, 158.96, 151.75,
150.50, 138.94, 136.69, 131.57, 129.78, 125.98, 123.95, 122.72,
121.21, 119.12, 118.58, 116.09, 115.86, 115.24; IR (KBr): 3054,
1708, 1690, 1645, 1534, 1340, 1266, 1044 cm1; HR-MS (ESIþ)
m/z: calcd. for C17H11ClN3Oþ3 : 340.0483, found 340.0498.
N-(1H-Benzo[d]imidazol-2-yl)-6-nitro-2-oxo-2H-chromen-3-
carboxamide (5e): Yield: 56%; yellow amorphous solid;
mp4290 1C; 1H NMR: δ 9.15 (s, 1H), 8.84 (d, 1H, J¼2.72 Hz),
8.41–8.52 (m, 1H), 8.31–8.34 (m, 1H), 7.61–7.70 (m, 1H), 7.40–
7.45 (m, 1H), 7.33–7.35 (m, 1H), 7.20–7.22 (m, 2H), 6.89 (br s,
1H); 13C NMR: δ 163.29, 159.48, 158.65, 151.21, 145.89, 140.27,
139.94, 124.45, 124.45, 124.24, 123.79, 123.50, 122.11, 119.01,
117.12, 116.81, 114.97; IR (KBr): 3050, 1738, 1709, 1680, 1561,
1529, 1268, 1229 cm1; HR-MS (þESI) m/z: calcd. for
C17H11N4Oþ5 : 351.0724, found 351.0740.
4.2. Anti-inﬂammatory activity
The inﬂammation was induced by injecting 0.1 mL of formalin in
subplantular region of rat's hind paw. Animals were divided into
various groups each of six rats. The control group received vehicle
(0.5% sodium carboxymethylcellulose (SCMC)) whereas the
standard groups received the standard drug indomethacin at a
dose of 20 mg/kg orally. Various test groups were administered
test compounds at the dose equimolar to the standard drug 1 h
prior to the formalin injection. The paw volume was measured by
plethysmograph and the change in paw volume was noted
periodically over 0–6 h29. The inhibition was calculated by the
formula reported by Chu and Kovacs30.
Inhibitionð%Þ ¼ 100
½ðoedema volume in treated=oedema volume in controlÞ  1004.3. Antioxidant activity
4.3.1. DPPH assay
The antioxidant activity of the test compounds was evaluated in
terms of hydrogen donating or radical scavenging ability with the
DPPH method taking BHT as standard drug31. The activity was
evaluated by taking different concentrations of each test and
standard compound. 700 mL of each concentration of the standard
solution of ascorbic acid and test compounds in methanol was
mixed with the same volume of methanolic solution of 700 mmol/L
DPPH. The mixed solution was shaken vigorously, allowed to
stand in dark at room temperature for 30 min and its absorbance
was read at 515 nm using a UV–Vis spectrophotometer (Beckman,
USA). The standard/test solution was replaced with methanol to
serve as control. The antiradical activity was calculated in terms of
inhibition using the following equation: [(AbsControlAbsTest)/
AbsControl] 100%. Different sample concentrations of each test
compound and standard were used in order to obtain a calibrationcurve for each test compound as well as BHT was constructed by
taking inhibition(%) as abscissa and concentration as coordinate to
calculate the EC50 values (the concentration required to obtain a
50% radical scavenging activity). Data analysis was performed as
reported by Locatelli et al.23 to compute EC50 on the basis of
probit regression. The antioxidant activity of each test compound
was performed in triplicate and EC50 values are reported as
mean7standard deviation (SD).
4.3.2. In vivo biochemical estimations
Glandular parts of the extracted stomachs were homogenized in
cold phosphate buffer (pH 7.4) for 2 min. The homogenized
contents were centrifuged at 800 g for 10 min followed by
centrifugation at 12,000 g for 15 min. The resulting supernatant
was used for catalase32, lipid peroxidation (LPO)33 and glutathione
reductase assays34.
4.4. Chronic ulcerogenicity test
Albino rats were used to perform this test. The control group
received vehicle whereas the test group and the standard group
received the test compounds (4 and 5, respectively) and the
standard drug (indomethacin) at the therapeutic dose for anti-
inﬂammatory effects for a period of 28 days orally. The rats were
then sacriﬁced and the stomach was removed and opened along
the greater curvature. The inner surface was washed slowly with
normal saline and was examined for the severity of ulceration
according to the following scale: 0¼normal grey coloured
stomach, 0.5¼pink to red colouration of stomach, 1¼spot ulcer,
1.5¼haemorrhagic ulcer, 2¼ulcero5, 3¼ulcer45, 4¼ulcers
with bleeding. Mean ulcer score for the control, standard and
each test compound was calculated and reported as ulcer index35.
4.5. Statistical analysis
All results were expressed as mean7SD. The statistical signiﬁ-
cance was determined by one-way analysis of variance (ANOVA)
followed by Dunnet's test and the results were found signiﬁcant at
Po0.05.
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